Similar to aging, cancer is a state where cells lose their original identity. By applying age-reversal technologies, cancer cells can be forced to become normal again or even self-destruct, offering a novel approach to cancer treatment.

K-36's epigenetic drug focuses on reversing the malignant programming of cancer cells. This approach aims to resensitize tumors to other treatments, making combination therapies the core strategy for achieving more durable responses, rather than relying on monotherapy to kill cells directly.

Instead of digital screening, Sethera Therapeutics generates vast physical libraries of hundreds of trillions of unique peptides within a small test tube. Each peptide is given a unique barcode, enabling researchers to test them against real biological targets and identify effective molecules from infinitesimally small quantities.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

Zelenorstat inhibits NMT, an enzyme that attaches a "GPS tag" to proteins, guiding them within the cell. By blocking this process, it renders key cancer-driving proteins useless, effectively confusing the cancer's operating system rather than using brute-force poison like chemotherapy.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Medicine is shifting from a 200-year-old paradigm of using chemical drugs to block symptoms toward a new era of cell and gene therapies. This new approach fundamentally changes treatment by directly addressing the root cause of disease: repairing or replacing the faulty cells and genes themselves.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

Antibodies bind to specific amino acid sequences, making them unable to distinguish between a protein's healthy and toxic structural forms. Alt-Pep's synthetic peptides use a complementary structure (alpha-sheet) to selectively bind only the toxic oligomers, enabling both targeted therapy and highly specific diagnostics.